Rockwell Medical Appoints Jim McCarthy as New SVP, Business and Corporate Development

September 4, 2018 at 4:30 PM EDT

WIXOM, Mich., Sept. 4, 2018 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today announced that Jim McCarthy, has been appointed Senior Vice President, Corporate and Business Development, effective September 4, 2018. In this newly-formed role, Mr. McCarthy will report to Stuart Paul, whose appointment as Chief Executive Officer of Rockwell Medical also became effective today. Mr. McCarthy previously served as a Business Development Consultant for Rockwell Medical.

Mr. McCarthy is a seasoned business development executive with more than three decades of experience in the life sciences industry, including a twenty-five year career with Bristol-Myers Squibb, a publicly-traded global biopharmaceutical company. During that time, he gained significant domestic and international corporate business development experience, executing a broad range of transactions including licensing deals, strategic alliances and acquisitions. More recently, Mr. McCarthy has served in numerous roles assisting small and emerging life science companies with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis. In addition, he has held leading roles in the Licensing Executive Society as Chair of the Life Sciences Sector and with the Licensing Executive Society International Life Sciences Leadership Committee. He holds an MBA from Indiana University and a B.S. in Physical Therapy from SUNY Upstate Medical Center, and is a recipient of the Certified Licensing Professional designation.

Mr. Paul said, "On behalf of the Company, we are pleased to officially welcome Jim as a full-time member of our team. Jim has extensive knowledge in business planning and product marketing and brings a track record of successfully executing upon commercialization strategies in a wide-range of therapeutic areas. In addition, he has significant experience leading corporate development activities, both in the U.S. and internationally. We are confident that Jim's leadership skills and relevant experience will be an asset to our new management team."

Mr. McCarthy said, "I am excited to join Rockwell Medical at this important time in its evolution. I look forward to working closely with Stuart and the rest of the talented team as we explore growth opportunities for our two innovative renal drug therapies and work to best position the Company for success."

About Rockwell Medical, Inc. 
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD). Rockwell Medical's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Rockwell's FDA approved generic drug Calcitriol (active vitamin D) is for treating secondary hyperparathyroidism in patients undergoing chronic renal dialysis. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates (used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream) to dialysis providers and distributors in the U.S. and abroad. Please visit for more information.

Forward-Looking Statement
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to bring to market Triferic and Calcitriol. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "plan," "potential," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include: statements about our liquidity and capital resources; our ability to maintain compliance with SEC and NASDAQ rules and requirements; plans relating to the commercialization of Triferic and Calcitriol; the timing and ability of the Company to obtain add-on reimbursement for Triferic; the Company's ability to obtain FDA and EMA approval of the intraveneous formulation of Triferic; and whether the Company can successfully execute on its new business strategy. Rockwell expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Dan Katcher / Kelly Sullivan / Arielle Rothstein  
Joele Frank, Wilkinson Brimmer Katcher   

Cision View original content:

SOURCE Rockwell Medical, Inc.